Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Roflumilast serves up weight-loss benefit for patients with psoriasis
In the treatment of patients with psoriasis, the phosphodiesterase (PDE)-4 inhibitor roflumilast has been found to also induce weight loss.
Roflumilast serves up weight-loss benefit for patients with psoriasis
20 Oct 2023
Face mask use tied to cardiovascular symptoms
Use of face masks remains an effective method in preventing COVID-19 transmission, but a recent study in Singapore has found that wearing of face masks is also associated with more self-reported cardiovascular symptoms.
Face mask use tied to cardiovascular symptoms
20 Oct 2023
Newly diagnosed T2D linked to earlier CVD events
A new diagnosis of type 2 diabetes (T2D) raises the risk of cardiovascular disease (CVD) development within 10 years in both men and women and across age groups, particularly among younger patients, reveals a recent study.
Newly diagnosed T2D linked to earlier CVD events
20 Oct 2023
Beta strain-containing bivalent vaccine protects against various SARS-CoV-2 variants
A Beta variant-containing vaccine conferred protection against different SARS-CoV-2 variants, with an acceptable safety profile in adults <60 years, a phase III trial has shown.
Beta strain-containing bivalent vaccine protects against various SARS-CoV-2 variants
20 Oct 2023
Postpartum depression more common in pregnant women with rheumatic disease
Women of reproductive age with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), or rheumatoid arthritis (RA) are more likely to experience postpartum depression than those without any rheumatic disease (RD), according to a study.
Postpartum depression more common in pregnant women with rheumatic disease
19 Oct 2023
GLP-1RA, SGLT2i superior to DPP-4i at preventing stroke, death in T2D patients
Among type 2 diabetes (T2D) patients with and without comorbid cardiovascular disease, those who have been newly initiated to glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose cotransporter 2 inhibitors (SGLT2i) appear to enjoy greater reductions in the risks of stroke and death when compared with new users of dipeptidyl peptidase-4 inhibitors (DPP-4i), suggests a study.
